Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

被引：25

作者：

Robin, Marie ^{[1
]}

Porcher, Raphael ^{[2
,3
]}

Orvain, Corentin ^{[4
]}

Bay, Jacques-Olivier ^{[5
]}

Barraco, Fiorenza ^{[6
]}

Huynh, Anne ^{[7
]}

Charbonnier, Amandine ^{[8
]}

Forcade, Edouard ^{[9
]}

Chantepie, Sylvain ^{[10
]}

Bulabois, Claude ^{[11
]}

Yakoub-Agha, Ibrahim ^{[12
]}

Detrait, Marie ^{[13
]}

Michonneau, David ^{[14
]}

Turlure, Pascal ^{[15
]}

Raus, Nicole ^{[16
]}

Boyer, Francoise ^{[4
]}

Suarez, Felipe ^{[17
]}

Vincent, Laure ^{[18
]}

Guyen, Stephanie N. ^{[19
]}

Cornillon, Jerome ^{[20
]}

Villate, Alban ^{[21
]}

Dupriez, Brigitte ^{[22
]}

Cassinat, Bruno ^{[23
]}

Rolland, Valerie ^{[24
]}

Schlageter, Marie Helene ^{[23
]}

Socie, Gerard ^{[14
]}

Kiladjian, Jean-Jacques ^{[25
]}

机构：

[1] Hop St Louis, AP HP, Serv Hematol Greffe, Paris, France

[2] Univ Paris, INSERM, Epidemiol & Stat Res Ctr CRESS, INRA, Paris, France

[3] Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin, Paris, France

[4] CHU Angers, Angers, France

[5] CHU Clermont Ferrand, Clermont Ferrand, France

[6] CHU Lyon Sud, Lyon, France

[7] CHU Toulouse, Toulouse, France

[8] CHU Amiens, Amiens, France

[9] CHU Bordeaux, Serv Hematol & Therapie Cellulaire, Bordeaux, France

[10] CHU Caen, Caen, France

[11] CHU Grenoble Alpes, Grenoble, France

[12] Univ Lille, CHU Lille, INSERM U1286, Infinite, Lille, France

[13] Univ Lorraine, Inst Louis Mathieu, CHRU Nancy, Vandoeuvre Les Nancy, France

[14] Univ Paris, Serv Hematol Greffe, Hop St Louis, AP HP,U976, Paris, France

[15] CHU Limoges, Limoges, France

[16] Hop Lyon Sud, SFGM TC, Lyon, France

[17] CHU, Hop Necker, AP HP, Paris, France

[18] CHU Montpellier, Hop St Eloi, Montpellier, France

[19] Hop La Pitie Salpetriere, APHP, Paris, France

[20] Inst Cancerol Loire, St Etienne, France

[21] CHRU Tours, Hop Bretonneau, Tours, France

[22] Ctr Hosp, Route Bassee, Lens, France

[23] Hop St Louis, AP HP, Lab Biol Cellulaire, Paris, France

[24] CHU Lyon Sud, FILO, Lyon, France

[25] Hop St Louis, AP HP, Ctr Invest Clin, Paris, France

来源：

BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / 08期

关键词：

D O I：

10.1038/s41409-021-01252-7

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

This multicenter prospective phase 2 trial analyzed disease-free survival (DFS) in myelofibrosis patients receiving ruxolitinib for 6 months before transplantation. Seventy-six patients were recruited. Age-adjusted dynamic international prognostic scoring system was intermediate-1, intermediate-2, and high in 27 (36%), 31 (41%), and 18 (24%) patients. All patients received ruxolitinib from inclusion to conditioning regimen (fludarabine-melphalan) or to progression. A donor was found in 64 patients: 18 HLA-matched sibling donor (MSD), 32 HLA-matched unrelated (UD10/10), and 14 HLA mismatched unrelated donor (UD9/10. Among 64 patients with a donor, 20 (31%) achieved a partial response before transplantation and 59 (92%) could be transplanted after ruxolitinib therapy (18/18 MSD, 30/21 UD10/10, 11/34 UD9/10), of whom 19 (32%) were splenectomized. Overall survival from inclusion was 68% at 12 months. One-year DFS after transplantation was 55%: 83%, 40%, and 34% after MSD, UD10/10 or UD9/10, respectively. Cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) was 66% and non-relapse-mortality was 42% at 12 months. Short course of ruxolitinib before transplantation is followed by a high rate of transplantation. With the platform used in this protocol, outcome was much better in patients transplanted with HLA-matched sibling donor as compared to unrelated donor.

引用

页码：1888 / 1899

页数：12

共 41 条

[1] Sample size tables for exact single-stage phase II designs [J].

A'Hern, RP .

STATISTICS IN MEDICINE, 2001, 20 (06) :859-866

[2] Outcome of Transplantation for Myelofibrosis [J].

Ballen, Karen K. ;

Shrestha, Smriti ;

Sobocinski, Kathleen A. ;

Zhang, Mei-Jie ;

Bashey, Asad ;

Bolwell, Brian J. ;

Cervantes, Francisco ;

Devine, Steven M. ;

Gale, Robert Peter ;

Gupta, Vikas ;

Hahn, Theresa E. ;

Hogan, William J. ;

Kroeger, Nicolaus ;

Litzow, Mark R. ;

Marks, David I. ;

Maziarz, Richard T. ;

McCarthy, Philip L. ;

Schiller, Gary ;

Schouten, Harry C. ;

Roy, Vivek ;

Wiernik, Peter H. ;

Horowitz, Mary M. ;

Giralt, Sergio A. ;

Arora, Mukta .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) :358-367

[3] Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes [J].

Bannow, Bethany T. Samuelson ;

Salit, Rachel B. ;

Storer, Barry E. ;

Stevens, Emily A. ;

Wu, David ;

Yeung, Cecilia ;

Fang, Min ;

Petersdorf, Effie W. ;

Linenberger, Michael L. ;

Woo, Janghee ;

Sorror, Mohamed L. ;

Doney, Kris ;

Sandmaier, Brenda M. ;

Deeg, H. Joachim ;

Scott, Bart L. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (02) :386-392

[4] Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation [J].

Beauverd, Yan ;

Samii, Kaveh .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (05) :498-501

[5] Tumour lysis syndrome: new therapeutic strategies and classification [J].

Cairo, MS ;

Bishop, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (01) :3-11

[6] Does ruxolitinib prolong the survival of patients with myelofibrosis? [J].

Cervantes, Francisco ;

Pereira, Arturo .

BLOOD, 2017, 129 (07) :832-837

[7] Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation [J].

Chhabra, Saurabh ;

Liu, Ying ;

Hemmer, Michael T. ;

Costa, Luciano ;

Pidala, Joseph A. ;

Courie, Daniel R. ;

Alousi, Amin M. ;

Majhai, Navneet S. ;

Stuart, Robert K. ;

Kim, Dennis ;

Ringden, Olle ;

Urbano-Ispizua, Alvaro ;

Saad, Ayman ;

Savani, Bipin N. ;

Cooper, Brenda ;

Marks, David I. ;

Socie, Gerard ;

Schouten, Harry C. ;

Schoemans, Helene ;

Abdel-Azim, Hisham ;

Yared, Jean ;

Cahn, Jean-Yves ;

Wagner, John ;

Antin, Joseph H. ;

Verdonck, Leo F. ;

Lehmann, Leslie ;

Aljurf, Mahmoud D. ;

MacMillan, Margaret L. ;

Litzow, Mark R. ;

Solh, Melhem M. ;

Qayed, Muna ;

Hematti, Peiman ;

Kamble, Rammurti T. ;

Vij, Ravi ;

Hayashi, Roberti ;

Gale, Robert P. ;

Martino, Rodrigo ;

Seo, Sachiko ;

Hashmi, Shahrukh K. ;

Nishihori, Taiga ;

Teshima, Takanori ;

Gergis, Usama ;

Inamoto, Yoshihiro ;

Spellman, Stephen R. ;

Arora, Mukta ;

Hamilton, Betty K. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (01) :73-85

[8] A life-threatening ruxolitinib discontinuation syndrome [J].

Coltro, Giacomo ;

Mannelli, Francesco ;

Guglielmelli, Paola ;

Pacilli, Annalisa ;

Bosi, Alberto ;

Vannucchi, Alessandro Maria .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) :833-838

[9] Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis [J].

Dai, Tong ;

Friedman, Ellen W. ;

Barta, Stefan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :E430-E432

[10] Allogeneic hematopoietic stem cell transplantation for myelofibrosis [J].

Deeg, HJ ;

Gooley, TA ;

Flowers, MED ;

Sale, GE ;

Slattery, JT ;

Anasetti, C ;

Chauncey, TR ;

Doney, K ;

Georges, GE ;

Kiem, HP ;

Martin, PJ ;

Petersdorf, EW ;

Radich, J ;

Sanders, JE ;

Sandmaier, BM ;

Warren, EH ;

Witherspoon, RP ;

Storb, R ;

Appelbaum, FR .

BLOOD, 2003, 102 (12) :3912-3918

← 1 2 3 4 5 →